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ABSTRACT
Objective: To determine the ideal conditions for use of
the 23-valent pneumococcal polysaccharide vaccine
(PPV23) in older outpatients with chronic pulmonary
diseases.
Design: Prospective cohort study.
Participants: 1378 outpatients with chronic
pulmonary diseases $60 years of age.
Intervention: Participants were educated about
PPV23, and those who responded afﬁrmatively were
vaccinated between August and November 2002. The
participants who chose no intervention served as
controls. The prevaccine period was deﬁned as August
2001 to August 2002. Participants were followed for
2 years from December 2002 or until death.
Main outcome measures: Events of interest
included the ﬁrst episode of bacterial (including
pneumococcal) pulmonary infection (primary endpoint)
and death of any cause (secondary endpoint).
Results: Frequent episodes of pulmonary infection
during the prevaccine period signiﬁcantly decreased
event-free survival during the 2-year observation
period (p<0.001). Chronic respiratory failure was
associated with a decreased event-free survival only
when the pulmonary infection episode did not occur in
the prevaccine period (p<0.001). No signiﬁcant
differences in event-free survival were observed
between the vaccinated and unvaccinated group during
analysis of the entire cohort. In the Cox proportional
hazards regression model, event-free survival
decreased signiﬁcantly when pulmonary infection
occurred in the prevaccine period. In the subgroup
analysis, the ﬁrst episode of bacterial pulmonary
infection (but not death of any cause) was reduced
signiﬁcantly by PPV23 only in patients with chronic
respiratory failure who had no episodes of pulmonary
infection during the prevaccine period (p¼0.019).
Conclusion: The efﬁcacy of PPV23 against pulmonary
infection and death of any cause might be
unachievable if pulmonary infection occurs during the
prevaccine period. PPV23 needs to be given to older
patients with chronic pulmonary disease at an earlier
time in which infectious complications in the lung have
not yet occurred.
INTRODUCTION
Streptococcus pneumoniae continues to be one
of the main causative pathogens in commu-
nity-acquired pneumonia and meningitis.
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ARTICLE SUMMARY
Article focus (hypothesis)
- The efﬁcacy of pneumococcal polysaccharide
vaccine (PPV23) might be compromised by an
episode of pulmonary infection in the prevaccine
period or chronic respiratory failure in older
patients with chronic pulmonary disease.
Key messages
- The PPV23 efﬁcacy might be unachievable if
pulmonary infection occurs during the prevac-
cine period.
- The episode of pulmonary infection could be
prevented by PPV23 in older patients with non-
infectious complications such as chronic respi-
ratory failure.
- Older patients with chronic pulmonary disease
need to receive the PPV23 vaccination at an
earlier time in which infectious complications in
the lung have not yet occurred.
Strengths and limitations of this study
- Only participants who responded afﬁrmatively
received PPV23. They were not assigned
randomly to a group.
- The diagnosis of pneumococcal pulmonary
disease was not made in the majority of patients
who had pulmonary infection during the study
period. The microbiological diagnosis in the
lower respiratory tract, which is not normally
sterile, is ambiguous.
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Open Access ResearchOwing to the high mortality of S pneumoniae infections,
especially in older and very young patients, prophylactic
use of 23-valent pneumococcal polysaccharide vaccine
(PPV23) is recommended for people at an increased risk
of pneumococcal disease in developed countries.
3e7 The
efﬁcacy of PPV23, however, remains controversial.
Despite the fact that the results of pre and postlicensed
trials in immunocompetent people were supportive of
regulatory approval of vaccine use, clinical studies in
older or young adults with comorbidities in developed
countries produced little convincing evidence of effec-
tiveness against a common manifestation of pneumo-
coccal infections such as pneumonia.
8e12 A retrospective
study conducted in 1999 suggested that PPV23 was
associated with signiﬁcant reductions in hospitalisation
and mortalities of older patients with chronic lung
disease and contributed to medical-care cost savings,
although meta-analytical reviews published thereafter
failed to show any statistically signiﬁcant evidence of
the protective effects of PPV23 against the development
of pneumonia in older patients with chronic
illnesses.
13e15
We previously reported a 2-year cohort clinical study of
older outpatients with chronic pulmonary disease to
investigate the prophylactic effects of PPV23 on bacterial
and pneumococcal pulmonary infection onset and
outcome.
16 Analysis of the comparison between the
vaccinated and unvaccinated group showed a decline in
the incidence of bacterial pulmonary infection only in
the vaccinated group. This result might be associated
with PPV23 effectiveness, although detailed background
information regarding underlying pulmonary conditions
was not provided. A subgroup analysis needs to be
carried out, since chronic pulmonary disease includes
various clinical and pathophysiological pictures. Under-
lying pulmonary diseases could cause chronic respiratory
failure if repeatedly complicated by lung infections, and
such heterogeneity may generate different outcomes
after vaccination.
17 We decided to reanalyse the data to
study the inﬂuence of clinical background during the
prevaccine period on PPV23 efﬁcacy in older patients
with chronic pulmonary disease.
METHODS
Study population
All the outpatients $60 years of age (a total of 1378
participants at the start of the study) with chronic
pulmonary disease in the Kanagawa Cardiovascular and
Respiratory Diseases Centre were included in this study.
These patients were informed of the prophylactic effects
of PPV23 on infectious pulmonary exacerbations.
Chronic pulmonary diseases in this study included
bronchial asthma, chronic pulmonary emphysema, old
tuberculosis, chronic bronchitis, bronchiectasis, non-
tuberculous mycobacteria and others (table 1). Patients
who presented with a fever ($37.58C) were excluded
from the study according to the Preventive Vaccination
Law issued by the Japanese Ministry of Health, Labour
and Welfare. Once the clinical status of these patients
became stable, the patients were invited to participate in
the study. Home oxygen therapy (HOT) had been
prescribed according to the Japanese Respiratory
Society (JRS) Guidelines for 97 participants with chronic
respiratory failure upon study initiation (table 1), but
Table 1 Baseline characteristics of 1378 outpatients with chronic pulmonary disease
Frequency of pulmonary infection during the
prevaccine period
p Value* 0( n [1164) 1 (n[167) >1( n [43)
Age
Mean6SD 71.367.0 73.366.9 73.067.0 <0.001
Median 71 73 73
Male 626 (53.8%) 98 (58.7%) 27 (62.8%) 0.272
Female 538 (46.2%) 69 (41.3%) 16 (37.2%)
Chronic respiratory diseasey
Bronchial asthma 517 59 16
Chronic pulmonary emphysema 197 40 14
Old tuberculosis 157 33 10
Chronic bronchitis 106 18 5
Interstitial pneumonia 100 9 0
Non-tuberculous mycobacteria 84 10 2
Bronchioectasis 31 13 5
Others 103 15 4
Pneumococcal polysaccharide vaccine 23-vaccinated 512 (44.0%) 109 (65.3%) 25 (58.1%) <0.001
Pneumococcal polysaccharide vaccine 23-unvaccinated 652 (56.0%) 58 (34.7%) 18 (41.9%)
Chronic respiratory failure
+ 70 (6.0%) 20 (12.0%) 7 (16.3%) <0.001
  1094 (94.0%) 147 (88.0%) 36 (83.7%)
*Data were analysed using the Wilcoxon test or Pearson test.
ySome patients were diagnosed as having more than one chronic respiratory disease.
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observation period.
Study design
We did not adopt a randomised controlled study design,
since the PPV23 vaccination is considered a part of
standard care in many developed countries. Additionally,
some older participants with chronic pulmonary disease
were in an immunocompromised status; therefore,
a randomised controlled study of vaccine effectiveness
may violate ethical principles and human rights. Written
informed consent forms were obtained from all partici-
pants. To avoid selection bias, doctors and other medical
staff were not allowed to assign patients to the vaccine or
non-vaccine group; instead, individual patients decided
whether or not to be vaccinated. The same form, which
included an explanation of the study, was provided to all
the participants. A total of 647 patients were injected
with PPV23 (Pneumovax, Merck, Rahway, New Jersey)
intramuscularly into their non-dominant upper arm
between August and November 2002. The prevaccine
period was deﬁned as 1 year prior to PPV23 vaccination
(August 2001 to July 2002).
Data collection
Participants were followed from December 2002 to the
end of the study in November 2004 (for 2 years) or until
death in the clinic approximately every 2 months as long
as the clinical status remained stable. A diagnosis of
pulmonary infection was made by respiratory physicians
according to the Japanese Respiratory Society Guidelines
for the Management of Community-Acquired Pneu-
monia in Adults. In brief, pulmonary infection was
suspected if more than two of the following criteria were
met: temperature $37.08C, white-blood-cell count
>8000/mm
3 and C-reactive protein >0.7 mg/dl. A
diagnosis of pneumonia was made when chest radio-
graphs revealed alveolar opacities. If a cough with yellow
sputum production was observed in the absence of the
alveolar opacities on the chest radiograph, the patients
were diagnosed as having acute bronchitis or exacerba-
tion of chronic bronchitis. It was very difﬁcult to distin-
guish pneumonia clearly from acute bronchitis or an
acute exacerbation of chronic bronchitis in some
patients, since there were considerable clinical overlaps
between these illnesses including the symptoms, blood
test results, causative pathogens and antibiotic treat-
ment. Hence, pulmonary infection was expressed as
a dichotomous variable.
A diagnosis of pneumococcal pulmonary infection was
made if S pneumoniae was the dominant organism stained
with Gram stain in the sputum smear or if the sputum
culture was positive (>10
7 colony forming units/ml).
When S pneumoniae was not identiﬁed, patients were
diagnosed as having a pulmonary infection caused by an
identiﬁed pathogen or with a bacterial pulmonary
infection if no possible causative pathogen was detected
but if the clinical data were highly suggestive of bacterial
infection in the lung. Empirical antibiotic therapy was
started in all the patients promptly once clinical data
sufﬁcient to satisfy the deﬁnition of pulmonary infection
were obtained. The initial treatment was replaced by
second-line therapy of antibiotics chosen according to
the sensitivity results.
Event of interest
We hypothesised that repeated pulmonary infection and
concomitant gradual loss of lung function might be
related to a reduced PPV23 efﬁcacy. Participants were
grouped based on these factors: frequency of infectious
(including pneumococcal) pulmonary infection episode
within 1 year prior to the PPV23 vaccination (0 episodes,
1 episode and >1 episode) and chronic respiratory
failure represented by HOT usage. Events of interest
included the ﬁrst episode of bacterial or pneumococcal
pulmonary infection (pneumonia, acute bronchitis or
exacerbation of chronic bronchitis) where antibiotic
treatment was required (primary endpoint) and death of
any cause (secondary endpoint). The case of death with
missing values was not counted as an event of interest
but was included in the mortality.
Statistical analysis
Differences in event-free survival were depicted with
KaplaneMeier curves, and the logrank test was applied
for analysis. The primary and secondary endpoints (the
ﬁrst episode of pulmonary infection and death of any
cause, respectively) were analysed separately. Cross-
tabulated data were compared by the Wilcoxon test or
the Pearson c
2 test. Relative risks for the events were
estimated using the Cox proportional hazards regression
model. The covariates used in the analysis were: (1)
pulmonary infection during the prevaccine period, (2)
chronic respiratory failure and (3) PPV23 vaccination.
For further analysis, gender and age were added as
covariates, and the data were analysed. No other vari-
ables were regarded as covariates in relation to event-free
survival. Predictive Analytics Software statistics 18 and
SAS software were used for the statistical analysis.
RESULTS
Participant characteristics are shown in table 1. Signiﬁ-
cant reductions in vaccination rate, age and frequency of
chronic respiratory failure were observed in the group
without pulmonary infection during the prevaccine
period compared with the other two groups with at least
one episode of infectious lung complications. No
signiﬁcant gender difference was seen among groups.
The effects of underlying pulmonary conditions on
event occurrences were analysed before PPV23 effec-
tiveness was evaluated. Event-free survival in the
KaplaneMeier method dropped signiﬁcantly as the
frequency of pulmonary infection in the prevaccine
period increased: the ﬁrst episode of pulmonary
infection (ﬁgure 1); death of any cause (supplemental
ﬁgure A). Chronic respiratory failure was associated with
a signiﬁcant decrease in event-free survival only in the
absence of pulmonary infection in the prevaccine
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(supplemental ﬁgure B, table 2); death of any cause
(supplemental ﬁgure C, supplemental table A).
Participants were not randomly assigned to groups;
vaccination was chosen or declined by each individual.
As a result, the number of vaccinated patients was
signiﬁcantly higher than the number of unvaccinated
patients when pulmonary infection occurred during the
prevaccine period (table 1). No signiﬁcant PPV23
effectiveness against the development of ﬁrst episode of
pulmonary infection during the observation period was
seen between the vaccinated and unvaccinated group in
the KaplaneMeier method (supplemental ﬁgure D).
The mortality was, however, signiﬁcantly high in the
vaccinated group (supplemental ﬁgure E). This result
may be misleading owing to the vaccination imbalance
among groups. In the Cox proportional hazards regres-
sion model applied for covariate adjustment, no
hazardous effects of PPV23 on the incidence or timing of
the ﬁrst episode of pulmonary infection or death of any
cause were observed. The HR for the ﬁrst episode of
pulmonary infection or death of any cause increased
signiﬁcantly owing to some covariates such as pulmonary
infection during the prevaccine period and chronic
respiratory failure. Other covariates including gender
and age were not associated with the ﬁrst episode of
pulmonary infection but were associated with death of
any cause (table 3). The cause of death (n¼85) among
all the participants during the observation period is
shown in supplemental table B.
A subgroup analysis was performed to ﬁnd the ideal
condition for PPV23 use in older patients with chronic
pulmonary disease. There are no signiﬁcant differences
in pulmonary infection-free survival between vaccinated
and unvaccinated patients when grouped only by
frequency of pulmonary infection in the prevaccine
period (not shown). Pulmonary infection-free survival
was somewhat improved when patients with chronic
respiratory failure were vaccinated (p¼0.078). This
effectiveness became signiﬁcant when patients who had
at least one episode of pulmonary infection in the
prevaccine period were excluded (ﬁgure 2, table 4). The
mortality was not reduced by PPV23 in patients with
chronic respiratory failure who had no episodes of
pulmonary infection during the prevaccine period
(supplemental ﬁgure F). The cause of death (n¼9)
among patients with chronic respiratory failure who
had no episodes of pulmonary infection during the
prevaccine period was as follows: chronic respiratory
failure, two; cerebrovascular disease, two; and unknown,
one in vaccinated patients and chronic respiratory
failure, two; lung cancer, one; and unknown, one in
unvaccinated patients. In this group, PPV23 was shown
to have an effect on the ﬁrst episode of pulmonary
infection, but it did not reduce the number of deaths
owing to any cause.
There were only 29 pneumococcal pulmonary infec-
tion during the observation period (pneumococcal
pulmonary infection, 22; death, seven; supplemental
table C). The pneumococcal pneumonia-free survival
decreased signiﬁcantly in the presence of pulmonary
infection during the prevaccine period (p<0.001;
supplemental ﬁgure G). No effects of chronic respiratory
failure on pneumococcal pneumonia-free survival were
observed (p¼0.196). PPV23 vaccination did not show
Figure 1 KaplaneMeier curves showing the proportion of
patients free of the ﬁrst episode of pulmonary infection during
the observation period. Frequency of pulmonary infection
during the prevaccine period: (A) zero episodes; (B) one
episode; (C) more than one episode. EFS, event-free survival.
Table 2 Effects of pulmonary infection during the prevaccine period and chronic respiratory failure on pulmonary infection-free
survival after pneumococcal polysaccharide vaccine 23 vaccination
Frequency of pulmonary
infection during the
prevaccine period
Chronic respiratory
failure N Event*
Pulmonary infection-
free survival at the
end of the study* 95% CI p Valuey
0(  ) 1094 154 0.840 0.816 to 0.864 <0.001
0 (+) 70 19 0.653 0.525 to 0.781
1(  ) 147 59 0.550 0.462 to 0.638 0.506
1 (+) 20 10 0.409 0.168 to 0.649
>1(  ) 36 25 0.315 0.161 to 0.469 0.348
>1 (+) 7 6 0.143 0.000 to 0.402
*Event represented the number of patients who were diagnosed as having pulmonary infection during the observation period.
yData were analysed using the logrank test.
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ment of pneumococcal pneumonia (supplemental
ﬁgure H).
DISCUSSION
The effects of the PPV23 vaccination on older patients
with chronic pulmonary disease varied in accordance
with the frequency of lung-infection episodes and the
presence of chronic respiratory failure during the
prevaccine period. Our ﬁndings suggest the following:
PPV23 vaccination might work effectively unless
previous lung-infection episodes had occurred, and
a subgroup analysis of the underlying disease associated
with pneumococcal complications might be useful for
ﬁnding the possible ideal conditions for PPV23 use. To
our knowledge, this is the ﬁrst report to characterise
PPV23 effectiveness owing to the heterogeneity of
underlying lung conditions such as the presence of
pulmonary-infection episodes prior to vaccination or
chronic pulmonary failure in older patients with chronic
pulmonary disease.
Comparison with other studies
Previous pulmonary infection was highly associated with
poor clinical prognosis. This ﬁnding suggests that
beneﬁcial PPV23 effectiveness might be unachievable for
older people with chronic pulmonary disease in the
presence of infectious complications during the prevac-
cine period. In a multicentre, double-blind controlled
study conducted in Sweden, PPV23 was not efﬁcacious
against overall pneumonia in middle-aged or older non-
immunocompromised individuals who had been treated
for community-acquired pneumonia.
18 In that study, the
survival rate calculated by the KaplaneMeier method
was still >80% in both vaccinated and unvaccinated
populations after a 2-year observation, while our results
showed that the survival rate was <60% if episodes of
pulmonary infection had occurred within 1 year prior to
vaccination. These results are consistent with previous
suggestions that chronic pulmonary disease such as
chronic obstructive pulmonary disease (COPD) is a risk
factor for repeated pneumonia and that protective
effects of PPV23 could not be obtained.
19e21 Conﬂicting
results were shown in some other reports in which the
beneﬁcial effects of PPV23 in patients with COPD were
indicated, although previous episodes of pneumonia
prior to vaccination were not considered, and partici-
pants were not limited to older people.
13 22 Alfageme
et al showed PPV23 effectiveness in patients <65 years of
age with COPD in a randomised controlled study in 596
Table 3 Association of the frequency of pulmonary infection during the prevaccine period, chronic respiratory failure,
pneumococcal polysaccharide vaccine 23, gender and age with the ﬁrst episode of pulmonary infection or death of any cause
HR (95% CI) p Value
Covariates for the risk of the ﬁrst episode of pulmonary infection
Pulmonary infection during the prevaccine period
1 episode 3.251* (2.436 to 4.338) <0.001
>1 episode 6.480* (4.380 to 9.589) <0.001
Chronic respiratory failure 1.767 (1.227 to 2.546) 0.002
Pneumococcal polysaccharide vaccine 23 vaccination 1.096 (0.848 to 1.416) 0.396
Gender 0.911 (0.712 to 1.166) 0.457
Age 0.994 (0.976 to 1.013) 0.553
Covariates for the risk of death of any cause
Pulmonary infection during the prevaccine period
1 episode 2.289* (1.380 to 3.797) 0.001
>1 episode 3.134* (1.486 to 6.612) 0.003
Chronic respiratory failure 2.152 (1.234 to 3.752) 0.007
Pneumococcal polysaccharide vaccine 23 vaccination 0.795 (0.499 to 1.264) 0.332
Gender 0.340 (0.199 to 0.580) <0.001
Age 1.040 (1.008 to 1.072) 0.014
*HR was estimated in relation to the case of outpatients with no episode of pulmonary infection during the prevaccine period.
Figure 2 KaplaneMeier curves showing the proportion of
patients free of the ﬁrst episode of pulmonary infection during
the observation period. Patients with chronic respiratory failure
who had no episodes of pulmonary infection during the
prevaccine period: (A) unvaccinated; (B) vaccinated.
EFS, event-free survival.
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23 These results and data indicate that PPV23
might be inefﬁcacious in the older population with
chronic pulmonary disease, especially when complicated
by lung infection prior to the vaccination. Despite the
strong evidence of PPV23 efﬁcacy against invasive
pneumococcal disease, altered immune response,
disruption of a physical barrier in the airways owing to
progressive chronic pulmonary disease and repeated
pulmonary infection could compromise the beneﬁts.
12 4
PPV23 vaccination should be given to patients with
chronic pulmonary disease at an earlier stage in which
infectious complications have not yet occurred.
The probability of survival was signiﬁcantly increased
by PPV23 in the presence of chronic respiratory failure in
patients without any episodes of pulmonary infection
during the prevaccine period. The pulmonary infection-
free survival rate was 75.5% at the end of the observation
period when PPV23 was given. Without PPV23, survival
was reduced to 45.0%, almost the same level as that in
the case where infectious lung complications had
occurred during the prevaccine period. This result
indicates that pulmonary infection owing to chronic
respiratory failure could be prevented by the PPV23
vaccination. Oxygen therapy and inhalation therapy
containing corticosteroids may be administered in COPD
patients when airﬂow is severe, and chronic respiratory
failure is present, but these treatments were suggested to
be risk factors for community-acquired pneumonia.
25e27
Additionally, bacterial colonisation of the distal airway
may occur owing to the altered pulmonary defence.
24 We
suggest that patients receive the PPV23 vaccination soon
after the diagnosis of chronic respiratory disease such as
COPD, especially when maintenance treatments for
impaired lung function are expected to be risk factors
for pneumonia. In this study, the number of participants
with chronic respiratory failure who were free of lung
infections during the prevaccine period was only 70.
Thus, a large-scale study is warranted.
Strengths and limitations of the study
When informed consent was obtained prior to the study
initiation, PPV23 vaccine recommendations were made,
and only participants who responded afﬁrmatively
received the vaccination. This method may be associated
with these results: the vaccination rate increased signiﬁ-
cantly in high-risk patients who had at least one episode
of bacterial pulmonary infection during the prevaccine
period or chronic respiratory failure, and the mortality
was higher in vaccinated patients, although the presence
of adverse effects of PPV23 is unlikely because PPV23
had generally been considered safe based on clinical
experience since 1977.
7 In the Cox proportional hazards
model, PPV23 was not a risk factor for the events. All of
the participants in this study were older patients with
chronic pulmonary disease, and all of them could be
categorised into groups for which PPV23 vaccination is
recommended in the USA and some European coun-
tries.
371 4In Japan, no vaccine recommendations against
pneumococcal infection are issued by the Japanese
Ministry of Health, Labour and Welfare.
11 Japanese
participants need to accept some risks for the public
beneﬁt, and not for their own, if selected for the
unvaccinated group. This condition is different from
that in some developed countries where unvaccinated
control subjects in clinical trials of the PPV23 vaccine
could still be protected by previous vaccination and
indirect immunity from other people, including child-
ren.
28e30 Pneumococcal infection was associated with
increasing mortalities, while the beneﬁcial effects of
PPV23 without any severe adverse events were suggested
in some previous clinical trials.
1 8 15 31 32 Therefore, we
decided to conduct a non-randomised clinical study to
ensure that participants were treated with respect and
dignity.
The doctors had access to the patients’ vaccination
record during the observation period. However, at the
time of this study, PPV23 had already been approved by
the Japanese Ministry of Health, Labour and Welfare,
and there were no conﬂicts of interest with pharma-
ceutical companies. All the treatments were supported
by the public healthcare system funded by the Japanese
government; no speciﬁc grants were provided from any
funding agencies. Diagnosis of pulmonary infection was
made according to the same diagnostic criteria. There-
fore, it is unlikely that treatment bias occurred during
the observation period.
Table 4 Inﬂuence of pulmonary infection during the prevaccine period and chronic respiratory failure on the pneumococcal
polysaccharide vaccine 23 vaccine efﬁcacy
Frequency of pulmonary
infection during the
prevaccine period
Chronic respiratory
failure Vaccinated* Unvaccinated* p Valuey
( )(  ) 0.846 (465) 0.836 (629) 0.931
(+) 0.755 (47) 0.450 (23) 0.019
1 episode ( ) 0.557 (92) 0.490 (55) 0.665
(+) 0.431 (17) 0.333 (3) 0.876
>1 episode ( ) 0.317 (22) 0.214 (13) 0.200
(+) 0.000 (3) 0.250 (4) 0.093
*Data represented the pulmonary infection-free survival (%) at the end of the study (2 years after pneumococcal polysaccharide vaccine 23
vaccination). Numbers in parentheses indicate numbers of patients.
yData were analysed using the logrank test.
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in the majority of patients who had pulmonary infections
during the observation period. Identiﬁcation of S pneu-
moniae using a sputum Gram stain is required for
deﬁnitive diagnosis. However, compared with invasive
pneumococcal disease deﬁned as any condition in which
S pneumonia is identiﬁed in a normally sterile body site,
microbiological diagnosis in the lower respiratory tract is
ambiguous.
1 5 It was noted by many authors that respi-
ratory secretion samples for pneumococcal identiﬁca-
tion might be unreliable owing to the technical
difﬁculties in obtaining good-quality sputum and in
distinguishing causative specimens from colonisation.
21
The positive results in urine antigen testing might be
related to previous infection or colonisation.
33 It might
be difﬁcult to assess PPV23 effectiveness on pneumo-
coccal pulmonary infection using these procedures.
Blood cultures are recommended for patients hospital-
ised after a diagnosis of community-acquired pneu-
monia, although its cost-effectiveness has been
questioned in several studies.
34 Less expensive, novel
techniques for accurate diagnosis of pneumonia need to
be developed.
Conclusions and policy implications
These data demonstrated that the beneﬁcial effects of
the PPV23 vaccination may not be obtainable if an
episode of pulmonary infection occurred during the
prevaccine period in older patients with chronic
pulmonary disease. We suggest that PPV23 needs to be
given soon after chronic pulmonary disease is diagnosed.
In developed countries, including Japan, older popula-
tions with chronic pulmonary disease are growing in
number. The Japanese Ministry of Health, Labour and
Welfare should introduce the PPV23 vaccination for
patients with chronic pulmonary disease and in routine
vaccination of children along with pneumococcal
conjugate vaccine that could provide indirect beneﬁcial
effects to the population in whom PPV23 efﬁcacy may
not be expected.
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